Replies to post #3868 on BioCurex, Inc.(fka BOCX)

[Kag]

Confused? Hardly.

No wonder Abbott is taking so long to determine its "feasibility review." They have to develop a RECAF blood test to run on their automated analyzers and also have to deal with the varying amounts of RECAF in normal people. It is not difficult to understand why the first milestone is a "feasibility review." The varying amounts of RECAF in the blood of normal people has the potential to be a huge problem for early detection tests. BioCurex has been working on this problem since March 2002 (over 4 years ago) and essentially said in the May 16, 2006 press release that they do not know if it is solvable or not. kag